Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
116076 trials found · Page 1663 of 5804
-
Sound waves instead of scalpel: new study targets brain tumors in kids
Disease control Recruiting nowThe goal of this prospective, non-randomized, single-arm, feasibility study is to develop data to evaluate the safety and feasibility of ExAblate 4000 treatment of benign intracranial tumors which require clinical intervention in pediatric and young adult subjects. Indication of…
Phase: NA • Sponsor: InSightec • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC
-
New drug cocktail targets tough cancers in early trial
Disease control TerminatedThis research study is studying a combination of drugs as a possible treatment for cancer that might have a specific change in the phosphatidylinositol-3 phosphate (PI3K) pathway.
Phase: PHASE1 • Sponsor: Dana-Farber Cancer Institute • Aim: Disease control
Last updated Jun 27, 2026 09:05 UTC
-
Can a common antihistamine help heal the optic nerve?
Disease control Recruiting nowThe main purpose of this study is to assess clemastine as a remyelinating agent in patients with acute optic neuritis.The study will also evaluate the tolerability of clemastine, originally approved as first-generation antihistamine, in patients with optic neuritis. Study procedu…
Phase: PHASE2 • Sponsor: University of California, San Francisco • Aim: Disease control
Last updated Jun 27, 2026 11:01 UTC
-
New ablation combo may keep AFib at bay longer
Disease control CompletedThe purpose of this study it to learn whether pulmonary vein isolation (PVI) along with ablation of the posterior left atrial wall (PLAW) will reduce the likelihood of atrial fibrillation (AF) recurrence in patients with persistent or long-standing persistent AF one year after an…
Phase: NA • Sponsor: Arash Aryana, MD • Aim: Disease control
Last updated Jun 27, 2026 07:56 UTC
-
Ulcerative colitis drug filgotinib tested for Long-Term safety in over 1,100 patients
Disease control OngoingThe primary objective of this study is to observe the long-term safety of filgotinib in adults who have completed or met protocol specified efficacy discontinuation criteria in a prior filgotinib treatment study in ulcerative colitis (UC).
Phase: PHASE3 • Sponsor: Alfasigma S.p.A. • Aim: Disease control
Last updated Jun 27, 2026 12:36 UTC
-
Could 3 weeks of radiation be as good as 5 for breast cancer?
Symptom relief OngoingTo compare how often cancer recurs (comes back) after 3 weeks of radiation compared to 5 weeks of radiation in patients who receive radiation therapy delivered to the lymph nodes near the breast. The side effects that can develop during or after radiation treatment, including how…
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Symptom relief
Last updated Jul 17, 2026 00:00 UTC
-
New Three-Drug cocktail targets Hard-to-Treat lymphoma
Disease control OngoingThis phase I study studies the side effects and best dose of venetoclax and lenalidomide when given together with obinutuzumab in treating patients with B-cell non-Hodgkin lymphoma that has returned after a period of improvement or not responding to treatment. Monoclonal antibodi…
Phase: PHASE1 • Sponsor: Beth Christian • Aim: Disease control
Last updated Jun 26, 2026 15:12 UTC
-
New drug combo offers hope for elderly breast cancer patients avoiding surgery
Disease control CompletedThis phase II clinical trial studies how well fulvestrant and palbociclib works in treating older patients with breast cancer that responds to hormone treatment (hormone responsive) that cannot be removed by surgery. Estrogen can cause the growth of estrogen-receptor-positive bre…
Phase: PHASE2 • Sponsor: Ohio State University Comprehensive Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 08:05 UTC
-
New probe aims to stop post-polypectomy bleeding in high-risk patients
Prevention OngoingThe primary specific aim is to perform a randomized controlled trial (RCT) to compare rates of delayed hemorrhage after DEP detection of arterial blood flow and focal treatment in PPIU's (treatment arm) with standard treatment using medical guidelines alone (controls) for prevent…
Phase: NA • Sponsor: VA Office of Research and Development • Aim: Prevention
Last updated Jun 27, 2026 13:08 UTC
-
Breast cancer overdiagnosis? landmark trial tests monitoring vs. surgery for Low-Risk DCIS
Disease control OngoingA substantial number of DCIS lesions will never form a health hazard, particularly if it concerns slow-growing low-risk DCIS (grade I and II). This implies that many women might be unnecessarily going through intensive treatment resulting in a decrease in quality of life and an i…
Phase: NA • Sponsor: The Netherlands Cancer Institute • Aim: Disease control
Last updated Jun 27, 2026 08:14 UTC
-
New hope for brain cancer? drug shows promise in early trial
Disease control OngoingThis research study is studying a targeted therapy as a possible treatment for recurrent glioblastoma (GBM). The following intervention will be used in this study: -Abemaciclib
Phase: PHASE2 • Sponsor: Dana-Farber Cancer Institute • Aim: Disease control
Last updated Jun 26, 2026 12:48 UTC
-
New combo targets debilitating fatigue in advanced cancer patients
Symptom relief OngoingThis phase II trial studies how well anamorelin hydrochloride, physical activity, and nutritional counseling work in decreasing cancer-related fatigue in patients with incurable solid tumors that have spread to other parts of the body or have come back. Anamorelin hydrochloride, …
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Symptom relief
Last updated Jun 27, 2026 14:00 UTC
-
New drug combo shows promise for advanced breast cancer
Disease control CompletedThis is a non-randomized, open-label, single-arm, multicenter, phase II study of palbociclib in combination with tamoxifen in women with HR(+)/HER2(-) advanced breast cancer who have not received prior systemic anticancer therapies for their advanced/metastatic disease.
Phase: PHASE2 • Sponsor: Oana Danciu, MD • Aim: Disease control
Last updated Jun 27, 2026 08:12 UTC
-
Electric zaps to the brain may help veterans remember words
Symptom relief CompletedA debilitating and common symptom in Gulf War Illnesses (GWI) is the inability to retrieve words. This affects one's conversations, ability to fluidly exchange information verbally and retrieve information from memory. The investigators have discovered 3 brain regions - the PreSu…
Phase: NA • Sponsor: The University of Texas at Dallas • Aim: Symptom relief
Last updated Jun 27, 2026 08:11 UTC
-
New drug combo aims to boost immune attack on melanoma
Disease control OngoingThis phase I trial studies the best dose of ibrutinib when given together with pembrolizumab in treating patients with stage III-IV melanoma that cannot be removed by surgery. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attac…
Phase: PHASE1 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated Jul 09, 2026 00:00 UTC
-
Experimental liposomal chemo shows promise in kids with relapsed leukemia
Disease control CompletedThis is a pilot study utilizing Marqibo® (vincristine sulfate liposome injection) combined with dexamethasone, mitoxantrone and asparaginase (UK ALL R3) for relapsed acute lymphoblastic leukemia (ALL).
Phase: PHASE1 • Sponsor: Therapeutic Advances in Childhood Leukemia Consortium • Aim: Disease control
Last updated Jun 27, 2026 07:55 UTC
-
New drug duo aims to outsmart stubborn cancers
Disease control OngoingHyPeR is a multi-centre Phase 1 Dose Escalation Study of Guadecitabine (SGI-110)/ASTX727 a Second Generation Hypo-Methylating Agent in Combination with Pembrolizumab (MK3475) in Patients with Refractory Solid Tumours. The investigators will be investigating the safety and toxicit…
Phase: PHASE1 • Sponsor: Royal Marsden NHS Foundation Trust • Aim: Disease control
Last updated Jun 27, 2026 12:32 UTC
-
Weight loss program aims to cut cancer risk in BRCA and lynch syndrome carriers
Disease control OngoingThis trial studies how well weight management and health behavior intervention works in helping patients with hereditary breast and ovarian cancer and Lynch syndrome mutation carriers lose or maintain a healthy weight and lower their risk for cancer. Lifestyle behaviors such as p…
Phase: NA • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:08 UTC
-
Immune booster before chemo shows promise for tough breast cancer
Disease control OngoingThis study is a 2-cohort, open-label, multicenter, phase 2 study of a short course of immunotherapy consisting of sequential decitabine followed by pembrolizumab administered prior to a standard neoadjuvant chemotherapy regimen for patients with locally advanced HER2-negative bre…
Phase: PHASE2 • Sponsor: Virginia Commonwealth University • Aim: Disease control
Last updated Jul 03, 2026 00:00 UTC
-
New hope for brain tumor patients: targeted drug shows promise in early trial
Disease control OngoingThis is a study to assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and anti-tumor activity of DS-1001b in patients with gliomas that harbor IDH1-R132 mutations.
Phase: PHASE1 • Sponsor: Daiichi Sankyo • Aim: Disease control
Last updated Jun 27, 2026 09:01 UTC